Medicine's New Epicenter? Epigenetics

Flipping cancer's "off" switch.

Talk about this article with other patients, caregivers, and advocates in the Childhood CURE discussion group.
Longtime cancer researcher Jean-Pierre Issa, MD, recalls the evening in May of 1992, when he sat in a San Diego hotel room leafing through the program for the American Association for Cancer Research annual conference. Among the thousands of presentations listed, he spotted only two that mentioned epigenetics. One of them was his. 

These days, he’s not feeling so alone. In fact, the more research reveals about epigenetics, the more crowded the scientific gatherings get. Epigenetics is looking like it may become just as important—if not more so—than genetics itself in shaping the future of cancer treatment, diagnosis, and even prevention. It is, as one researcher wrote earlier this year, “at the epicenter of modern medicine.”

Not bad for a concept pushed to the margins of cancer research just a decade ago. “It’s something that was completely unexpected,” says Tanya Hoodbhoy, PhD, of the National Institutes of Health. “People thought genetics was it.”

Epigenetics isn’t new—the word first appeared in scientific circles decades ago. But the full appreciation of epigenetics didn’t begin to emerge until the 1990s at the height of excitement for the Human Genome Project, but epigenetics was simply outshone by its star counterpart. From 1989 to 2003 researchers undertook a historic endeavor to map the 20,000 or so genes that make people into people. The hope was to decode the genes, compare flawed genes with intact ones, and reveal secrets of human diseases such as cancer.

Yet, as researchers waded deeper into the study of human genes, the genetic coding of a malignant cell often turned out to be, by all appearances, normal. So what would make a cell with no mutations go so horribly awry? The problem wasn’t necessarily with the genes themselves. There had to be something else.

The human genome still retains its status as the blueprint for the body. But the epigenome—the way the genome is marked and packaged inside a cell’s nucleus—tells a cell which of the many sets of instructions on that blueprint to follow, which ones to ignore, and which ones to follow over and over again. If the genome is the blueprint, the epigenome is the contractor directing how the walls and windows are made, and whether the plumbing is correctly installed.

Because it has the power to switch our genes off and on, epigenetics is the reason that a skin cell doesn’t look or act like a liver cell, even though they both carry the same DNA. Epigenetics is the reason that identical twins, even though they are pretty much genetic clones of one another, don’t get the same diseases. And it is often the reason that a perfectly normal cell goes bad.

“When a group of investigators started talking about this in the early ’90s, there was considerable skepticism at the time,” says Issa, of M.D. Anderson Cancer Center in Houston.

Talk about this article with other patients, caregivers, and advocates in the Childhood CURE discussion group.
Special Feature
Share Your Art
Related Articles
Shannon Kerr isn't shy about proclaiming her status as a cancer survivor. At the 2016 Battlefrog Fiesta Bowl in Phoenix, Kerr was joined by a stadium full of fans in drawing attention to the disease and the toll it can take.
Grudge Match: My Journey With Chronic Myeloid Leukemia
Why does a cancer diagnosis always come down to being a winner or a loser?
FDA Approves Extended Therapy With Arzerra for Chronic Lymphocytic Leukemia
The approval was based on a near doubling in progression-free survival (PFS) seen with the treatment compared with observation in the phase 3 PROLONG trial.
Related Videos
Danielle Friedman on a Study of Diabetes Among Childhood Cancer Survivors
CURE spoke to Friedman during the 2016 Cancer Survivorship Symposium in mid-January.
Karen Duffy Pays Tribute to One of Our MPN Heroes
Karen Duffy pays tribute to her husband, Harvey Lawrence Gould, who was named one of our 2015 MPN Heroes.
Jason R. Gotlib Discusses MPN Research at Stanford
Jason R. Gotlib discusses the research being done at his institution. Gotlib is a 2015 MPN Hero in the category of Commitment to the Individual and is also an international leader in MPN research.